Connect with us

Life Sciences

Holy immunity! Bat genes key against COVID, cancer

Bats have acquired remarkable traits throughout their evolution. They’re the only mammals that can fly, and they live much longer than other animals…

Published

on

This article was originally published by BioEngineering

Bats have acquired remarkable traits throughout their evolution. They’re the only mammals that can fly, and they live much longer than other animals their size. But perhaps most impressive is their robust immune system. It protects bats from viruses that wreak havoc in humans, like COVID-19 or Ebola. It also keeps bats relatively cancer-free. How?

Jamaican fruit bat

Credit: McCombie and Siepel labs/Cold Spring Harbor Laboratory

Bats have acquired remarkable traits throughout their evolution. They’re the only mammals that can fly, and they live much longer than other animals their size. But perhaps most impressive is their robust immune system. It protects bats from viruses that wreak havoc in humans, like COVID-19 or Ebola. It also keeps bats relatively cancer-free. How?

According to Cold Spring Harbor Laboratory (CSHL) scientists, it’s all in the genes.

Using samples collected in Belize with Nancy Simmons from the American Museum of Natural History, CSHL Professors W. Richard McCombie and Adam Siepel and postdoc Armin Scheben sequenced the genomes of the Jamaican fruit bat and Mesoamerican mustached bat. When they compared these sequences to other mammals, the team found that rapid evolution has streamlined bat genomes to defend against infection and cancer. McCombie explains:

“We didn’t know immune system genes were so positively selected in bat genomes. Bats have a number of very unusual things about them. They don’t respond to infections the way we do. In retrospect, it’s not surprising this difference in the immune system may be involved in both the aging and cancer response.”

The Jamaican fruit bat and Mesoamerican mustached bat belong to the world’s most ecologically diverse superfamily of mammals. McCombie, Siepel, and Scheben created complete genomes for both bats using new Oxford Nanopore sequencing technology. They then compared these sequences to 15 other bat and mammal genomes, including humans. This revealed an unknown shift in levels of two inflammatory protein-coding genes called interferon-alpha and -omega.

“Bats have dialed down the immune system’s alarm by shedding genes that produce interferon-alpha,” Scheben explains. “This may be responsible for their high viral tolerance. It prevents overactive immune responses that harm healthy tissue—one of the reasons infections are so damaging to humans.”

They also found that compared to other mammals, bat genomes contain more changes in cancer-related genes, including six that repair DNA and 46 that suppress tumors.

“Our work highlights how immunity and cancer response are deeply interconnected,” Scheben says. “The same immune genes and proteins play important roles in cancer resistance.”

McCombie, Siepel, and Scheben are now exploring how bats’ immune genes are regulated and how they might be expressed in different parts of the body. They hope their work will provide new insights into the links between immunity, aging, and cancer. It may also one day lead to improved treatments.

“There’s still a lot of unknowns,” Siepel says. “Ultimately, we’ll take the work as far as we can and hand off the baton to experts in disease to work toward developing drugs or other therapeutics.”


Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending